South Korea · Delayed Price · Currency is KRW High Tech Pharm Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 207.03 billion. The enterprise value is 192.63 billion.
| Market Cap | 207.03B |
| Enterprise Value | 192.63B |
Important Dates
The next estimated earnings date is Wednesday, April 15, 2026.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | 0.25% |
| Float | 5.83M |
Valuation Ratios
The trailing PE ratio is 18.04.
| PE Ratio | 18.04 |
| Forward PE | n/a |
| PS Ratio | 2.95 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | 13.71 |
| P/OCF Ratio | 12.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.54, with an EV/FCF ratio of 12.76.
| EV / Earnings | 16.79 |
| EV / Sales | 2.74 |
| EV / EBITDA | 10.54 |
| EV / EBIT | 14.98 |
| EV / FCF | 12.76 |
Financial Position
The company has a current ratio of 5.67, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.67 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 71.36 |
Financial Efficiency
Return on equity (ROE) is 9.17% and return on invested capital (ROIC) is 9.26%.
| Return on Equity (ROE) | 9.17% |
| Return on Assets (ROA) | 5.66% |
| Return on Invested Capital (ROIC) | 9.26% |
| Return on Capital Employed (ROCE) | 9.80% |
| Weighted Average Cost of Capital (WACC) | 5.37% |
| Revenue Per Employee | 1.08B |
| Profits Per Employee | 176.54M |
| Employee Count | 65 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.36 |
Taxes
In the past 12 months, High Tech Pharm has paid 2.35 billion in taxes.
| Income Tax | 2.35B |
| Effective Tax Rate | 17.01% |
Stock Price Statistics
The stock price has increased by +49.08% in the last 52 weeks. The beta is 0.19, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +49.08% |
| 50-Day Moving Average | 16,625.80 |
| 200-Day Moving Average | 13,531.95 |
| Relative Strength Index (RSI) | 53.03 |
| Average Volume (20 Days) | 180,913 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 70.18 billion and earned 11.48 billion in profits.
| Revenue | 70.18B |
| Gross Profit | 16.94B |
| Operating Income | 12.86B |
| Pretax Income | 13.83B |
| Net Income | 11.48B |
| EBITDA | 18.27B |
| EBIT | 12.86B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 14.43 billion in cash and 33.61 million in debt, with a net cash position of 14.40 billion or 1,353.88 per share.
| Cash & Cash Equivalents | 14.43B |
| Total Debt | 33.61M |
| Net Cash | 14.40B |
| Net Cash Per Share | 1,353.88 |
| Equity (Book Value) | 130.67B |
| Book Value Per Share | n/a |
| Working Capital | 58.47B |
Cash Flow
In the last 12 months, operating cash flow was 17.03 billion and capital expenditures -1.93 billion, giving a free cash flow of 15.10 billion.
| Operating Cash Flow | 17.03B |
| Capital Expenditures | -1.93B |
| Depreciation & Amortization | 5.42B |
| Net Borrowing | -7.97B |
| Free Cash Flow | 15.10B |
| FCF Per Share | 1,420.24 |
Margins
Gross margin is 24.13%, with operating and profit margins of 18.32% and 16.35%.
| Gross Margin | 24.13% |
| Operating Margin | 18.32% |
| Pretax Margin | 19.70% |
| Profit Margin | 16.35% |
| EBITDA Margin | 26.04% |
| EBIT Margin | 18.32% |
| FCF Margin | 21.52% |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 0.77%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 0.77% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 9.27% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.73% |
| Earnings Yield | 5.54% |
| FCF Yield | 7.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 8.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.77 |
| Piotroski F-Score | 5 |